X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
index medicus (32) 32
female (30) 30
male (29) 29
adult (26) 26
middle aged (26) 26
endocrinology & metabolism (22) 22
cancer (21) 21
thyroid neoplasms - pathology (16) 16
life sciences (15) 15
thyroid cancer (15) 15
aged (12) 12
carcinoma (11) 11
treatment outcome (11) 11
thyroidectomy (10) 10
papillary (9) 9
prognosis (9) 9
metastases (8) 8
oncology (8) 8
adolescent (7) 7
aged, 80 and over (7) 7
iodine radioisotopes - therapeutic use (7) 7
management (7) 7
metastasis (7) 7
retrospective studies (7) 7
thyroid neoplasms - radiotherapy (7) 7
thyroid neoplasms - surgery (7) 7
tumors (7) 7
diagnosis (6) 6
follow-up studies (6) 6
france (6) 6
guidelines (6) 6
iodine radioisotopes (6) 6
thyroid neoplasms - metabolism (6) 6
[ sdv ] life sciences [q-bio] (5) 5
abridged index medicus (5) 5
care and treatment (5) 5
child (5) 5
disease progression (5) 5
fluorodeoxyglucose f18 (5) 5
iodine (5) 5
mutation (5) 5
patients (5) 5
prospective studies (5) 5
survival (5) 5
thyroid (5) 5
thyroid carcinoma (5) 5
thyroid neoplasms - diagnostic imaging (5) 5
thyroid neoplasms - epidemiology (5) 5
thyroid neoplasms - genetics (5) 5
[ sdv.can ] life sciences [q-bio]/cancer (4) 4
carcinoma - pathology (4) 4
carcinoma, papillary - pathology (4) 4
combined modality therapy (4) 4
hormone withdrawal (4) 4
mesh : humans (4) 4
pregnancy (4) 4
prostate cancer (4) 4
radioimmunotherapy (4) 4
radiopharmaceuticals (4) 4
sensitivity and specificity (4) 4
surgery (4) 4
thyroglobulin (4) 4
thyroglobulin - blood (4) 4
thyroid neoplasms - drug therapy (4) 4
thyroid neoplasms - therapy (4) 4
thyrotropin (4) 4
young adult (4) 4
adenocarcinoma, follicular - drug therapy (3) 3
adenocarcinoma, follicular - pathology (3) 3
bone metastases (3) 3
calcitonin (3) 3
cancer therapies (3) 3
carcinoma, papillary - surgery (3) 3
clinical trials (3) 3
disease (3) 3
doubling time (3) 3
follow-up (3) 3
france - epidemiology (3) 3
hyperthyroidism (3) 3
incidence (3) 3
infant (3) 3
infant, newborn (3) 3
medical prognosis (3) 3
medicine, general & internal (3) 3
medullary thyroid carcinoma (3) 3
mesh : adult (3) 3
mesh : aged (3) 3
mesh : male (3) 3
mesh : middle aged (3) 3
mesh : thyroid neoplasms (3) 3
neck (3) 3
neoplasm staging (3) 3
neuroendocrine tumors (3) 3
ophthalmopathy (3) 3
palliative treatment (3) 3
patient outcomes (3) 3
pet (3) 3
positron-emission-tomography (3) 3
quality of life (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 18, pp. 1663 - 1673
This trial compared two thyrotropin-stimulation methods and two 131I doses for postoperative ablation in patients with low-risk thyroid cancer. Rates of... 
RECOMBINANT HUMAN THYROTROPIN | CARCINOMA PATIENTS | MEDICINE, GENERAL & INTERNAL | STIMULATED THYROGLOBULIN | REMNANT ABLATION | HORMONE WITHDRAWAL | FOLLOW-UP | PREDICTIVE-VALUE | SERUM THYROGLOBULIN LEVELS | QUALITY-OF-LIFE | RADIOACTIVE IODINE | Adenocarcinoma, Follicular - radiotherapy | Follow-Up Studies | Neck - diagnostic imaging | Humans | Middle Aged | Ablation Techniques | Male | Iodine Radioisotopes - adverse effects | Iodine Radioisotopes - therapeutic use | Thyrotropin - adverse effects | Thyroid Hormones - blood | Adenocarcinoma, Follicular - drug therapy | Ultrasonography | Adult | Female | Thyrotropin - therapeutic use | Thyroid Hormones - therapeutic use | Adenocarcinoma, Follicular - surgery | Thyroid Neoplasms - surgery | Carcinoma, Papillary - drug therapy | Treatment Outcome | Combined Modality Therapy | Thyroid Neoplasms - radiotherapy | Carcinoma, Papillary - surgery | Thyroidectomy | Hypothyroidism - etiology | Carcinoma, Papillary - radiotherapy | Thyroid Neoplasms - drug therapy | Quality of Life | Drugs | Dose-response relationship (Biochemistry) | Treatment outcome | Evaluation | Usage | Care and treatment | Patient outcomes | Radiofrequency ablation | Product/Service Evaluations | Thyroid cancer | Thyrotropin | Dosage and administration | Drug therapy, Combination | Drug therapy | Isotopes | Iodine | Risk groups | Event-related potentials | Thyroid gland | Contamination | Thyroid carcinoma | Metastases | Thyroid-stimulating hormone | Thyroglobulin | Neck | Cancer | Thyroid
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2015, Volume 33, Issue 26, pp. 2885 - 2892
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 04/2019, Volume 104, Issue 4, pp. 1020 - 1028
Context: Recombinant human thyrotropin (rhTSH) has been shown to be an effective stimulation method for radioactive iodine (RAI) therapy in differentiated... 
LYMPH-NODE METASTASES | HIGH-RISK | GUIDELINES | ENDOCRINOLOGY & METABOLISM | HORMONE WITHDRAWAL | RADIOACTIVE IODINE | RADIOIODINE ABLATION | CARCINOMA | DOSE RADIOIODINE | HUMAN TSH | IODINE REMNANT ABLATION
Journal Article
Neurosurgery, ISSN 0148-396X, 08/2019
Dysthyroid optic neuropathy (DON) is a devastating complication of thyroid eye disease. Corticosteroids are the primary medical treatment for DON, but some... 
Journal Article
Nuclear Medicine Communications, ISSN 0143-3636, 09/2017, Volume 38, Issue 9, pp. 771 - 779
INTRODUCTIONMany studies have reported the high performance of 6-fluorine-18-fluorodihydroxyphenilalanine (F-FDOPA) PET/CT in the diagnosis of... 
Journal Article
British Journal of Ophthalmology, ISSN 0007-1161, 11/2015, Volume 99, Issue 11, pp. 1531 - 1535
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 08/2012, Volume 53, Issue 8, pp. 1185 - 1192
The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term survival based on such prognostic factors as serum calcitonin and... 
Doubling time | Bispecific antibody | CEA | Medullary thyroid carcinoma | Radioimmunotherapy | radioimmunotherapy | doubling time | CLINICAL-TRIAL | EFFICACY | LOCK METHOD | TOXICITY | KINASE INHIBITOR | PEPTIDE | BIVALENT HAPTEN | POSITRON-EMISSION-TOMOGRAPHY | bispecific antibody | CANCER XENOGRAFT | medullary thyroid carcinoma | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Humans | Middle Aged | Male | Pentetic Acid - immunology | Young Adult | Neoplasm Metastasis | Aged, 80 and over | Biomarkers, Tumor - metabolism | Radioimmunotherapy - methods | Adult | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoembryonic Antigen - immunology | Treatment Outcome | Thyroid Neoplasms - radiotherapy | Disease Progression | Antibodies, Bispecific - therapeutic use | Animals | Antibodies, Bispecific - adverse effects | Carcinoma, Neuroendocrine | Survival Analysis | Aged | Mice | Radioimmunotherapy - adverse effects | Thyroid Neoplasms - metabolism | Thyroid Neoplasms - pathology | Confidence intervals | Thyroid cancer | Disease | Medical treatment | Bone marrow | Clinical trials | Biomarkers | Indium | Cancer therapies | Cancer | Thyroid Neoplasms | Tumor Markers, Biological | Pentetic Acid | Life Sciences | Antibodies, Monoclonal, Humanized | Antibodies, Bispecific | Carcinoembryonic Antigen
Journal Article